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Long-Term Efﬁcacy and Safety of
Paclitaxel-Eluting Balloon for the
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3-Year Results of a Randomized Controlled TrialSebastian Kufner, MD,* Salvatore Cassese, MD,* Marco Valeskini, CAND MED,* Franz-Josef Neumann, MD,y
Stefanie Schulz-Schüpke, MD,*z Petra Hoppmann, MD,x Massimiliano Fusaro, MD,* Heribert Schunkert, MD,*z
Karl-Ludwig Laugwitz, MD,zx Adnan Kastrati, MD,*z Robert A. Byrne, MB, BCH, PHD,*
for the ISAR-DESIRE 3 InvestigatorsABSTRACTFro
Mu
Kr
ma
be
Bio
Ku
MaOBJECTIVES This study sought to investigate the long-term comparative efﬁcacy and safety of paclitaxel-eluting
balloon (PEB), paclitaxel-eluting stent (PES), or balloon angioplasty (BA) for the treatment of drug-eluting stent
restenosis.
BACKGROUND The optimal treatment of drug-eluting stent restenosis remains unknown. Although PEB has shown
encouraging results, the long-term clinical efﬁcacy and safety of PEB remains poorly deﬁned.
METHODS A total of 402 patients with clinically signiﬁcant restenosis in limus-eluting stents were randomly assigned
to receive PEB (n ¼ 137), PES (n ¼ 131), or BA (n ¼ 134). For this analysis, PEB versus PES and PEB versus BA were
compared. The primary efﬁcacy and safety endpoints were target lesion revascularization and the composite of death or
myocardial infarction.
RESULTS At a median follow-up of 3 years, the risk of target lesion revascularization was comparable with PEB versus
PES (hazard ratio [HR]: 1.46, 95% conﬁdence interval [CI]: 0.91 to 2.33; p ¼ 0.11) and lower with PEB versus BA (HR:
0.51, 95% CI: 0.34 to 0.74; p < 0.001). The risk of death/myocardial infarction tended to be lower with PEB versus PES
(HR: 0.55, 95% CI: 0.28 to 1.07; p ¼ 0.08), due to a lower risk of death (HR: 0.38, 95% CI: 0.17 to 0.87; p ¼ 0.02). The
risk of death/myocardial infarction was similar with PEB versus BA (HR: 0.96, 95% CI: 0.46 to 2.0; p ¼ 0.91).
CONCLUSIONS At 3 years, the use of PEB as compared with PES to treat patients with limus-eluting stent
restenosis has similar efﬁcacy and safety. PEB remains superior to BA. The sustained efﬁcacy without trade-off in
safety supports the role of PEB as treatment option for patients with drug-eluting stent restenosis. (Intracoronary
Stenting and Angiographic Results: Drug Eluting Stent In-Stent Restenosis: 3 Treatment Approaches [ISAR-DESIRE 3];
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ABBR EV I A T I ON S
AND ACRONYMS
BA = balloon angioplasty
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
MI = myocardial infarction
PEB = paclitaxel-eluting
balloon
PES = paclitaxel-eluting
stent(s)
TLR = target lesion
revascularization
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878I n patients with coronary artery di-sease requiring percutaneous coro-nary intervention, the implantation of
drug-eluting stents (DES) has superior anti-
restenotic efﬁcacy as compared with that of
bare metal stents (1,2). However, owing to
the overall increase in the use of DES and
the growing number of complex clinical and
lesion subsets treated, the absolute number
of patients with DES restenosis remains
considerable (3). Moreover, the optimal treat-
ment strategy for these patients is not clearly
established. Repeat stenting with DES is
widely practiced and previous studies havesupported this approach (4,5). Nevertheless, concerns
exist about the long-term sequelae of multiple stent
layers in the coronary vessel wall (6).SEE PAGE 885The use of balloon catheters coated with anti-
proliferative drugs has emerged as a promising tech-
nology (7). In particular, the use of paclitaxel-eluting
balloon (PEB) therapy for the treatment of reste-
nosis after DES has demonstrated encouraging
angiographic and short-term clinical results as
compared with DES or balloon angioplasty (BA) alone
(8,9). However, the long-term clinical efﬁcacy and
safety of PEB therapy in cases of restenosis after DES
has not been well evaluated. In the present report, we
evaluate the efﬁcacy and safety of PEB as compared
with paclitaxel-eluting stent (PES) or BA alone 3 years
after the treatment of DES restenosis in the setting
of the randomized ISAR-DESIRE 3 (Intracoronary
Stenting and Angiographic Results: Drug Eluting
Stent In-Stent Restenosis: 3 Treatment Approaches)
trial.
METHODS
STUDY POPULATION AND PROTOCOL. Patients were
enrolled between August 3, 2009, and October 27,
2011 in 3 German centers. Full details of the study
population, methods, endpoints, and primary anal-
ysis have been previously reported (10). In brief, pa-
tients were included if they met the following
criteria: were >18 years old; had ischemic symptoms
or evidence of myocardial ischemia (inducible or
spontaneous) in the presence of a restenosis $50%
located in a native vessel DES or proximal or dis-
tal margins; and had provided written, informed
consent. Patients with restenosis occurring in any
limus-eluting stent were considered eligible for
participation in the study. Patients were excluded if
they met any of the following criteria: had a targetlesion located in the left main stem or in a coronary
bypass graft; presented with acute ST-segment
elevation myocardial infarction within the preceding
48 h, cardiogenic shock, severe renal insufﬁciency
(deﬁned as glomerular ﬁltration rate #30 ml/min),
malignancies, or other comorbid conditions with life
expectancy <12 months or that may result in protocol
noncompliance; or had contraindications or known
allergy to antiplatelet therapy, paclitaxel, stainless
steel, or pregnancy (present, suspected or planned).
Patients were randomly assigned to receive open-
label PEB (SeQuent Please, B. Braun, Melsungen,
Germany), PES (Taxus Liberté, Boston Scientiﬁc,
Natick, Massachusetts), or BA alone. Detailed descrip-
tions of devices, drugs, and elution characteristics
have been reported previously (10). Patient allocation
to each of the 3 treatment groups was in equal pro-
portions. All patients were evaluated at 1, 12, and
36 months by phone contact or ofﬁce visit. An angio-
graphic follow-up was scheduled for all patients at
6 to 8 months.
The study was conducted in accordance with the
provisions of the Declaration of Helsinki and with
the International Conference on Harmonization Good
Clinical Practices. The trial protocol was approved by
the institutional ethics committee responsible for the
participating centers.
ENDPOINTS AND DEFINITIONS. The primary efﬁcacy
and safety endpoints of interest in the current anal-
ysis were the need for target lesion revascularization
(TLR) and the composite of death or myocardial
infarction (MI), respectively. Other outcomes of in-
terest were death, MI, target lesion thrombosis, and
major adverse cardiac event (the composite of TLR,
death, or MI).
Study deﬁnitions have been previously described
in detail (10).
STATISTICAL ANALYSIS. The results of the primary
analysis have already been published, and this addi-
tional analysis is exploratory in nature. Baseline
descriptive statistics are presented as mean  SD for
continuous variables and as counts or proportions (%)
for categorical variables. Differences across groups
were checked for signiﬁcance using analysis of vari-
ance for continuous data and chi-squared test
(or Fisher exact test where the expected cell value
was <5) for categorical variables. Survival was an-
alyzed according to Kaplan-Meier methods and haz-
ard ratio (HR) with pertinent 95% conﬁdence interval
(95% CI) was calculated using Cox proportional haz-
ards methods. The proportional hazards assumption
was checked by the method of Grambsch and Ther-
neau and was fulﬁlled in all cases in which we
TABLE 1 Baseline Clinical and Angiographic Characteristics According to
Treatment Group
PEB PES BA
Clinical Characteristics
(n ¼ 137) (n ¼ 131) (n ¼ 134)
Age, yrs 67.7  10.4 68.8  10.0 67.1  9.3
Female 32 (23.4) 43 (32.8) 39 (29.1)
Diabetes mellitus 56 (40.9) 61 (46.6) 50 (37.3)
Insulin-dependent 21 (15.3) 27 (20.6) 19 (14.2)
Hypertension 105 (76.6) 101 (77.1) 90 (67.2)
Hyperlipidemia 108 (78.8) 103 (78.6) 102 (76.1)
Current smoker 19 (13.9) 15 (11.5) 22 (16.4)
Previous MI 53 (38.7) 50 (38.2) 57 (42.5)
Previous CABG* 15 (11.0) 32 (24.4) 24 (17.9)
Multivessel disease 129 (94.2) 122 (93.1) 127 (94.8)
Clinical presentation
Acute coronary syndrome 26 (19.0) 22 (16.8) 31 (23.1)
Ejection fraction† 53.6  9.8 54.5  9.9 53.2  9.9
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879used Cox proportional hazards models (11). A land-
mark analysis explored the occurrence of primary
endpoints between 1- and 3-year follow-ups. Sum-
mary statistics were derived for comparisons of PEB
versus PES as well as of PEB versus BA alone,
respectively. Analysis of the primary efﬁcacy and
safety outcomes was also performed for the compar-
ison PEB versus PES according to pre-speciﬁed sub-
sets of interest (age [median value], sex, diabetic
status, and vessel size [median diameter]), and
interaction between treatment effect and these
covariates was assessed with Cox proportional haz-
ards models. All endpoints of interest for the current
analysis were analyzed on an intention-to-treat basis.
Statistical software S-PLUS (version 4.5, S-PLUS,
Insightful Corp, Seattle, Washington) was used for
analysis.Lesion and Procedural Characteristics
(172 Lesions) (168 Lesions) (160 Lesions)
Target vessel
LAD 59 (34.3) 50 (29.8) 52 (32.5)
LCX 54 (31.4) 61 (36.3) 56 (35.0)
RCA 59 (34.3) 56 (33.3) 52 (32.5)
LM 0 (0.0) 1 (0.6) 0 (0.0)
Index stent type
Biolimus-eluting 6 (3.5) 4 (2.4) 8 (5.0)
Everolimus-eluting 53 (30.8) 48 (28.6) 42 (26.3)
Sirolimus-eluting 82 (47.7) 94 (56.0) 90 (56.3)
Zotarolimus-eluting 31 (18.0) 22 (13.1) 20 (12.5)
Bifurcation 47 (27.3) 40 (23.8) 37 (23.1)
Vessel size, mm 2.75  0.50 2.80  0.49 2.72  0.45
Diameter stenosis, pre, % 64.4  16.8 66.7  16.5 67.7  15.7
MLD, pre, mm 0.97  0.48 0.93  0.50 0.88  0.49
MLD, post, mm‡ 2.29  0.44 2.53  0.48 2.10  0.49
Diameter stenosis, post, %§ 18.5  8.3 12.8  7.8 23.3  12.6
Values are mean  SD or n (%) unless otherwise indicated. Lesion characteristics are based on in-stent analysis.
*There were no signiﬁcant differences across the groups at baseline with the exception of previous CABG
(p ¼ 0.015). †Data available for 279 patients (73.9%). ‡The MLD post-procedure was signiﬁcantly lower for PEB
versus PES (p < 0.001) and signiﬁcantly higher for PEB versus BA (p < 0.001) and PES versus BA (p < 0.001).
§Diameter stenosis post-procedure was signiﬁcantly higher for PEB versus PES (p < 0.001) and signiﬁcantly
lower for PEB versus BA (p < 0.001) and PES versus BA (p < 0.001).
BA ¼ balloon angioplasty; CABG ¼ coronary artery bypass graft; LAD ¼ left anterior descending artery; LCX ¼
left circumﬂex artery; LM ¼ left main; MI ¼ myocardial infarction; MLD ¼ minimum lumen diameter; PEB ¼
paclitaxel-eluting balloon; PES ¼ paclitaxel-eluting stent(s); RCA ¼ right coronary artery.RESULTS
As previously reported, a total of 402 patients with
500 treated lesions were enrolled in this study:
137 patients (172 lesions) were treated with PEB;
131 patients (168 lesions) with PES; and 134 patients
(160 lesions) with BA. Baseline clinical, angiographic,
and procedural characteristics were similar across
treatment groups (Table 1). Clinical follow-up was
available for 363 patients (90.3%, median 3.0 years
[2.8 to 3.0 years]). Of patients with incomplete 3-year
clinical follow-up 13 (3.2%) had clinical follow-up
#2 years (median 1.4 years [1.0 to 1.7 years]).
PEB VERSUS PES FOR RESTENOSIS AFTER DES
IMPLANTATION. Regarding the primary efﬁcacy out-
come, TLR at 3 years occurred in 44 cases (33.3%)
with PEB and in 29 cases (24.2%) with PES (HR: 1.46,
95% CI: 0.91 to 2.33; p ¼ 0.11) (Figure 1A). TLR between
1 and 3 years occurred in 14 cases (14.5%) with PEB
and in 12 cases (12.4%) with PES (HR: 1.17, 95% CI:
0.54 to 2.53; p ¼ 0.69) (Figure 1B).
Regarding the primary safety outcome, the com-
posite of death or MI at 3 years occurred in 14 cases
(10.4%) with PEB and in 23 cases (18.3%) with PES
(HR: 0.55, 95% CI: 0.28 to 1.07; p ¼ 0.08) (Figure 2A).
Death or MI between 1 and 3 years occurred in
8 cases (6.3%) with PEB and in 14 cases (12.3%) with
PES (HR: 0.51, 95% CI: 0.21 to 1.22; p ¼ 0.12)
(Figure 2B). PEB as compared with PES showed a
signiﬁcant lower risk of death (6% vs. 15.3%, HR:
0.38, 95% CI: 0.17 to 0.87; p ¼ 0.02). At 3-year
follow-up, the risk of MI (5.4% vs. 3.2%, HR: 1.60,
95%CI: 0.47 to 5.48; p¼0.45), target lesion thrombosis
(0.8% vs. 1.6%, HR: 0.46, 95% CI: 0.04 to 5.10;
p ¼ 0.53), or major adverse cardiac events (38.0%vs. 37.7%, HR: 1.02, 95% CI: 0.69 to 1.52; p ¼ 0.91)
was comparable between PEB and PES (Table 2).
No signiﬁcant interaction was found between PEB
versus PES and the pre-speciﬁed subgroups in terms
of efﬁcacy and safety (Figure 3).
PEB VERSUS BA FOR RESTENOSIS AFTER DES IMPLAN-
TATION. Regarding the primary efﬁcacy outcome,
TLR at 3 years occurred in 44 cases (33.3%) with
PEB and in 65 cases (50.8%) with BA (HR: 0.51, 95%
CI: 0.34 to 0.74; p < 0.001) (Figure 1A). TLR be-
tween 1 and 3 years occurred in 14 cases (14.5%)
FIGURE 1 Cumulative Survival Analysis Curves and Landmark Analysis for TLR
Cumulative survival analysis curves at 3 years (A) and landmark analysis from 1 to 3 years (B) for target lesion revascularization (TLR) by treatment group. BA ¼ balloon
angioplasty; PEB ¼ paclitaxel-eluting balloon; PES ¼ paclitaxel-eluting stent(s).
FIGURE 2 Cumulat
Cumulative survival a
in Figure 1.
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880with PEB and in 9 cases (13.4%) with BA (HR: 1.04,
95% CI: 0.45 to 2.41; p ¼ 0.92) (Figure 1B).
Regarding the primary safety outcome, the com-
posite of death or MI at 3 years occurred in 14 cases
(10.4%) with PEB and in 14 cases (10.9%) with BA
(HR: 0.96, 95% CI: 0.46 to 2.00; p ¼ 0.90) (Figure 2A).
Death or MI between 1 and 3 years occurred in 8 cases
(6.3%) with PEB and in 5 cases (4.5%) with BA
(HR: 1.55, 95% CI: 0.51 to 4.75; p ¼ 0.44) (Figure 2B).
At 3-year follow-up, the risk of death (6% vs. 9.4%,
HR: 0.63, 95% CI: 0.26 to 1.54; p ¼ 0.31) or MI (5.4%
vs. 1.5%, HR: 3.34, 95% CI: 0.69 to 16.06; p ¼ 0.11) wasive Survival Analysis Curves and Landmark Analysis for Death or MI
nalysis curves at 3 years (A) and landmark analysis from 1 to 3 years (B) for decomparable with PEB versus BA. Conversely, PEB was
associated with a signiﬁcantly lower risk of major
adverse cardiac events than BA was (38.0% vs. 55.7%,
HR: 0.52, 95% CI: 0.37 to 0.75; p < 0.001) mainly
driven by the lower risk of TLR. There was no target
lesion thrombosis in the BA group (p ¼ 0.33 for PEB
vs. BA) (Table 2).
DISCUSSION
The ISAR-DESIRE 3 study was a randomized trial
comparing PEB versus PES or BA for the treatment ofath or myocardial infarction (MI) by treatment group. Abbreviations as
FIGURE 3 Comparison of Incidence of TLR and Death or MI According to Pre-Speciﬁed Subgroups
Comparison of incidence of TLR (A) and death or MI (B) according to pre-speciﬁed subgroups in patients treated with PEB versus PES. CI ¼ conﬁdence interval; other
abbreviations as in Figures 1 and 2.
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881patients with restenosis after DES implantation.
The current analysis is the ﬁrst report of long-term
outcomes of PEB in patients presenting with DES
restenosis. The principal ﬁndings are that at 3-year
follow-up, PEB as compared to PES shows overall
similar efﬁcacy and safety, and that PEB as compared
to BA shows sustained superior efﬁcacy.
Patients with restenosis after stenting represent a
high-risk cohort with increased risk of adverse events
in comparison with patients who remain restenosis
free (12). In particular, the treatment of patients with
DES restenosis is associated with poorer outcomes in
comparison with patients with bare-metal stent
restenosis (3,13). In the setting of DES restenosis, a
treatment strategy of repeat drug-eluting stenting has
been demonstrated to be effective and safe at short-
to mid-term follow-up even in high-risk subgroups
(4,14). However, concerns exist about the long-term
implications of multiple stent layers—the so-called
onion-skin phenomenon (3). By offering the possi-
bility to locally deliver sufﬁcient quantities of an
antiproliferative drug and obviating the need for
another stent layer, PEB is a potentially attractive
treatment option for these patients (7).
In the particular setting of restenosis after DES
implantation, PEB has demonstrated encouraging
short-term results as compared with repeat DES or BA
alone (8,9). However, although a report of long-term
outcomes after PEB use in patients with bare-metal
stent restenosis showed maintained efﬁcacy out to
5 years (15), long-term outcomes after PEB for DESrestenosis are not known. Indeed data suggest that
there may be important pathophysiological differ-
ences between restenosis after bare metal and drug-
eluting stenting (16). Moreover, pre-clinical reports
suggest that signs of delayed arterial healing can be
observed after PEB (17) and case reports have docu-
mented the occurrence of de novo atherosclerosis
after PEB for the treatment of in-stent restenosis (18).
Therefore, the evaluation of long-term outcomes in
these patients remains a matter of broad clinical
relevance.
The current analysis of 3-year outcome data
demonstrates the durable antirestenotic efﬁcacy of
PEB as compared with PES or BA. These data should
be interpreted in light of some recently reported re-
sults from other randomized trials. First, the sus-
tained superiority of PEB in comparison with BA is in
line with the recently presented 3-year results of the
PEPCAD-DES (Treatment of DES-In-Stent Restenosis
With SeQuent Please Paclitaxel Eluting PTCA Cath-
eter) randomized trial in which no signs of late
“catch-up” phenomenon were observed with PEB (19).
Indeed the low incidence of revascularization with
PEB between 1 and 3 years underscores that the
signiﬁcant difference in terms of efﬁcacy between
PEB and BA is achieved during the ﬁrst year after
treatment and suggests that a brief (typically 60 s)
dilation with a drug-eluting balloon results in long-
term sustained suppression of neointimal hyperpla-
sia. In view of the lower efﬁcacy, BA as a routine
treatment approach for DES restenosis in clinical
TABLE 2 Clinical Results at 3 Years and Landmark Analysis From 0 to 1 and 1 to 3 Years by Treatment Group
PEB PES BA
HR (95% CI)
PEB vs. PES
p Value
PEB vs. PES
HR (95% CI)
PEB vs. BA
p Value
PEB vs. BA
TLR
0–1 yr 30 (22.1) 17 (13.5) 56 (43.5) 1.65 (0.91–3.0) 0.09 0.41 (026–0.64) <0.001
1–3 yrs 14 (14.5) 12 (12.4) 9 (13.4) 1.17 (0.54–2.53) 0.69 1.04 (0.45–2.41) 0.92
0–3 yrs 44 (33.3) 29 (24.2) 65 (50.8) 1.46 (0.91–2.33) 0.11 0.51 (0.34–0.74) <0.001
Clinically driven TLR
0–1 yr 25 (18.5) 15 (11.9) 47 (36.5) 1.54 (0.81–2.93) 0.18 0.43 (0.26–0.69) <0.001
1–3 yrs 12 (12.0) 8 (8.2) 4 (5.1) 1.42 (0.58–3.48) 0.44 2.22 (0.72–6.89) 0.16
0–3 yrs 37 (28.1) 23 (19.1) 51 (39.5) 1.50 (0.89–2.53) 0.12 0.58 (0.38–0.88) 0.01
Death or MI
0–1 yr 6 (4.4) 9 (6.9) 9 (6.8) 0.62 (0.22–1.73) 0.35 0.62 (0.22–1.75) 0.36
1–3 yrs 8 (6.3) 14 (12.3) 5 (4.5) 0.51 (0.21–1.22) 0.12 1.55 (0.51–4.75) 0.44
0–3 yrs 14 (10.4) 23 (18.3) 14 (10.9) 0.55 (0.28–1.07) 0.08 0.96 (0.46–2.00) 0.90
Death
0–1 yr 3 (2.2) 6 (4.6) 7 (5.3) 0.46 (0.12–1.85) 0.27 0.40 (0.10–1.54) 0.17
1–3 yrs 5 (3.9) 13 (11.2) 5 (4.4) 0.34 (0.12–0.96) 0.03 0.95 (0.28–3.30) 0.94
0–3 yrs 8 (6.0) 19 (15.3) 12 (9.4) 0.38 (0.17–0.87) 0.02 0.63 (0.26–1.54) 0.31
Cardiac death
0–1 yr 2 (1.5) 5 (3.8) 4 (3.0) 0.37 (0.07–1.92) 0.22 0.47 (0.09–2.59) 0.38
1–3 yrs 1 (0.9) 5 (4.4) 2 (1.8) 0.18 (0.02–1.52) 0.07 0.48 (0.04–5.25) 0.54
0–3 yrs 3 (2.4) 10 (8.1) 6 (4.7) 0.27 (0.08–0.99) 0.03 0.48 (0.12–1.90) 0.28
MI
0–1 yr 3 (2.1) 3 (2.4) 2 (1.5) 0.92 (0.19–4.58) 0.92 1.42 (0.24–8.50) 0.63
1–3 yrs 4 (3.2) 1 (0.9) 0 (0.0) 3.63 (0.41–32.45) 0.22 NA 0.05
0–3 yrs 7 (5.4) 4 (3.2) 2 (1.5) 1.60 (0.47–5.48) 0.45 3.34 (0.69–16.06) 0.11
Q-wave MI
0–1 yr 1 (0.7) 1 (0.8) 0 (0.0) 0.92 (0.06–14.64) 0.95 NA 0.34
1–3 yrs 0 (0.0) 0 (0.0) 0 (0.0) NA 0.18 NA 0.69
0–3 yrs 1 (0.7) 1 (0.8) 0 (0.0) 0.92 (0.06–14.75) 0.96 NA 0.34
Target vessel–related MI
0–1 yr 0 (0.0) 2 (1.6) 1 (0.8) NA 0.14 NA 0.31
1–3 yrs 3 (2.3) 0 (0.0) 0 (0.0) NA 0.10 NA 0.09
0–3 yrs 3 (2.3) 2 (1.6) 1 (0.8) 1.36 (0.23–8.17) 0.73 2.84 (0.29–27.26) 0.35
Target lesion thrombosis
0–1 yr 1 (0.8) 1 (0.8) 0 (0.0) 0.94 (0.06–15.11) 0.97 NA 0.33
1–3 yrs 0 (0.0) 1 (0.8) 0 (0.0) NA 0.29 NA 0.69
0–3 yrs 1 (0.8) 2 (1.6) 0 (0.0) 0.46 (0.04–5.10) 0.53 NA 0.33
Death, MI, or TLR
0–1 yr 32 (23.5) 25 (19.3) 61 (46.2) 1.20 (0.71–2.02) 0.50 0.40 (0.26–0.62) <0.0001
1–3 yrs 19 (19.2) 23 (22.9) 12 (18.0) 0.83 (0.45–1.52) 0.54 1.08 (0.52–2.23) 0.83
0–3 yrs 51 (38.0) 48 (37.7) 73 (55.7) 1.02 (0.69–1.52) 0.91 0.52 (0.37–0.75) <0.001
Values are n (%) unless otherwise indicated. The percentages are Kaplan-Meier estimates. The p values were determined by log-rank test. Hazard ratios with pertinent 95%
conﬁdence intervals are derived from Cox proportional hazard models.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; NA ¼ not applicable; TLR ¼ target lesion revascularization; other abbreviations as in Table 1.
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882practice should be discouraged. In this study, in
patients treated with PEB, thorough pre-treatment
of the restenotic lesion was ﬁrst performed with
conventional BA; this is the recommended approach
for using PEB in clinical practice. Second, the com-
parable results observed with PEB in comparison
with repeat stenting with DES is encouraging and
lends support to the concept that by avoiding further
stent layers, a strategy based on PEB may be the
preferred treatment for these patients. Importantly,however, it should be acknowledged that the
comparator stent in ISAR-DESIRE 3 was the early
generation PES. Nevertheless, although PES has
been superseded by newer generation DES for the
treatment of de novo coronary disease, it has shown
comparable efﬁcacy to leading DES in the treatment
DES restenosis (4,14). At the same time, a random-
ized trial comparing new generation DES with PEB in
patients with bare-metal stent restenosis showed
some evidence of higher angiographic antirestenotic
PERSPECTIVES
WHAT IS KNOWN? Although PEB angioplasty has shown
encouraging results for the treatment of DES restenosis, the
long-term clinical efﬁcacy and safety of this therapy remains
poorly deﬁned.
WHAT IS NEW? In this study, the use of PEB as compared with
PES implantation to treat DES in-stent restenosis has similar
efﬁcacy and safety out to 3 years. In addition, PEB remains
superior to BA alone.
WHAT IS NEXT? The sustained efﬁcacy without trade-off in
safety supports the role of PEB as a treatment option for patients
with DES restenosis. These ﬁndings should be veriﬁed in larger
trials powered for clinical endpoints.
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883efﬁcacy with newer generation DES, although this
did not translate into signiﬁcant differences in terms
of clinical efﬁcacy (20). In addition, a recently pre-
sented randomized trial in patients with DES reste-
nosis suggests that a strategy of everolimus-eluting
stenting might offer superior efﬁcacy as compared
with a treatment with PEB, although the long-
term clinical impact of such strategy remains
unstudied (21).
Interestingly, in relation to safety outcomes in
terms of the composite of death or MI the current
analysis shows some evidence of higher safety with
PEB therapy compared with repeat stenting with PES
as well as comparable overall late safety versus BA
alone. In particular, the treatment of DES restenosis
with PEB versus PES seems to be associated with a
lower risk of death and cardiac death; this difference
is mainly driven by events occurring after 1 year.
Whereas analysis of late outcomes should be regarded
as post hoc, and this difference may represent a
chance ﬁnding, it is interesting to note that similar
observations have recently been presented in the
2-year follow-up of the PEPCAD China ISR (Prospec-
tive, Multicenter, Randomized Trial of Paclitaxel-
Coated Balloon versus Paclitaxel-Eluting Stent for
the Treatment of DES In-Stent Restenosis) trial (22).
Moreover, although a clear mechanistic link is not
apparent – despite a numerically lower risk of target
lesion thrombosis with PEB versus PES — this issue
warrants further investigation.
STUDY LIMITATIONS. First, the design of the ISAR-
DESIRE 3 trial was based on primary comparative
efﬁcacy between the treatment groups in relation to
angiographic endpoints at 6 to 8 months. Accord-
ingly, the trial was not speciﬁcally powered for the
detection of differences in clinical outcomes and
these ﬁndings should be veriﬁed in larger trials
powered for clinical endpoints. Second, as efﬁcacy
and safety among different paclitaxel-eluting bal-
loons may vary (7,23), the results observed in this
analysis might not be generalizable to other devices.
Third, the study protocol included angiographic
follow-up and the inﬂuence of planned inva-
sive surveillance on the rates of TLR must beconsidered. Fourth, although all treatment groups
received the same recommendation for duration of
treatment after index PCI (minimum of 6 months),
complete 3-year data relating to compliance or
actual duration of dual antiplatelet therapy received
was not available. Fifth, in patients with
DES restenosis, the results of a repeat stenting
treatment strategy might be improved with the use
of newer generation DES (21).CONCLUSIONS
At 3-year follow-up, the use of PEB as compared with
PES to treat restenosis in patients who have previ-
ously received a limus-eluting stent has similar efﬁ-
cacy and safety. In addition, PEB remains superior
to BA. The sustained efﬁcacy without trade-off in
safety supports the role of PEB as a treatment option
for patients with DES restenosis.
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